At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 265 enrolled
Drug / intervention
Artesunate-mefloquine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older
In Brief
A Phase 4 clinical trial evaluating Artesunate-mefloquine, Atovaquone-proguanil, and 1 other intervention for Malaria and Falciparum. Completed, enrolled 265 participants across 1 site.
Detailed Summary
To evaluate the potential effects of artemether- lumefantrine on the auditory function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Falciparum
CountriesColombia
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedMar 7, 2007
Enrollment StartMay 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.3 years ago
Interventions
Artesunate-mefloquinedrug
Atovaquone-proguanildrug
Artemether-lumefantrinedrug